Jump to main content
Hands on computer keyboard)

Press Releases

Press Releases


CSL Behring’s HEMGENIX® Granted First-Ever Direct Access in France for Haemophilia B Gene Therapy

13 Dec 2023

Global biotechnology leader CSL Behring (ASX: CSL) has been granted Direct Access for HEMGENIX® (etranacogene dezaparvovec) by the French Ministry of Health, marking the first treatment to be authorised by this innovative process in France.

Handover of baton at the head of CSL Behring in Marburg

29 Nov 2023

Dr Niklas Schier will join the management of CSL Behring GmbH as the third Managing Director alongside Michael Schroeder and Dr Lutz Bonacker and take over the management of the production site in Marburg from Michael Schroeder as of 1 January 2024.

Seven New CSL Global Research Acceleration Initiative Awardees Announced to Fast-Track Therapeutics Innovation

04 Oct 2023

CSL’s Global Research Acceleration Initiative Freshly Inks Promising Research Partnerships in Europe and, for the first time, Asia and the UK

Phase 3 Data on Garadacimab for HAE in Lancet

01 Mar 2023

Significant reduction in number of attacks support the potential of once-monthly garadacimab as a prophylactic therapy for patients with hereditary angioedema

First Gene Therapy for Hemophilia B, CSL Behring’s HEMGENIX®, Approved by the European Commission

20 Feb 2023

Approval of HEMGENIX® underscores CSL Behring’s promise to deliver life-changing innovations that have the potential to help patients lead full lives

Positive CHMP Opinion for Etranacogene Dezaparvovec

16 Dec 2022

Regulatory milestone moves CSL one step closer to bringing the promise of gene therapy for hemophilia B to patients in Europe

CSL R&D Day 2022 Highlights

03 Nov 2022

Pipeline advancements and investment in innovation and disruptive technologies to help fuel sustainable, profitable growth for CSL’s three businesses, CSL Behring, CSL Seqirus and CSL Vifor, in the decades ahead

CSL Behring donates to WFH

02 May 2022

500 Million IUs Coagulation Factor Replacement Therapy for the World Federation of Hemophilia Humanitarian Aid Program

EMA Review Gene Therapy for Hemophilia B

28 Mar 2022

EMA Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B

Gen Therapie Study Hämophilia B

04 Feb 2022

Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene Dezaparvovec Gene Therapy in Hemophilia B – Data Presented at EAHAD 2022

Agreement with uniQure on Gene Therapy

06 May 2021

• Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein that prevents excessive bleeding.

• uniQure will complete the Phase 3 HOPE-B trial and scale up manufacture for initial commercial supply under an agreed plan with CSL Behring.

CoVIg-19 Plasma Alliance Announces Topline Results from NIH-Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine

02 Apr 2021

Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints to show efficacy in adults hospitalized with COVID-19

CSL Australia Dispatches COVID 19 Vaccine

24 Mar 2021

CSL Dispatches First Australian Made Doses of the AstraZeneca COVID 19 Vaccine.

Read more news releases on our global corporate website here.

CSL Behring Media Contact

Stephanie Fuchs
Marburg, Deutschland
Mobile: +49 (0)151 58438860
stephanie.fuchs@cslbehring.com